Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

LongBio Pharma Raises HKD 1.25 Billion in Hong Kong IPO – Clinical-Stage Biotech Advances Anti-IgE and Bifunctional Complement Inhibitors for Allergic and Autoimmune Diseases

Fineline Cube May 28, 2026
Company Deals

Lantheus Holdings Receives $7 Billion Buyout Offer from Curium Pharma – Radiopharmaceutical Leader’s Alzheimer’s Portfolio Attracts Strategic Interest

Fineline Cube May 28, 2026
Company Deals

Viridian Therapeutics Secures Commercial Manufacturing Agreement with WuXi Biologics for Veligrotug – Anti-IGF-1R Antibody Advances Toward Thyroid Eye Disease Treatment

Fineline Cube May 28, 2026
Company Deals

Shanghai Pharma and Trinomab Partner to Commercialize Xintituo in Philippines – World’s First Recombinant Anti-Tetanus Toxin Monoclonal Antibody Expands Overseas

Fineline Cube May 28, 2026
Company Deals Drug

Shanghai Pharma Partners with BeOne Medicines on Imdelltra Distribution – Expanding Access to DLL3/CD3 Bispecific T-Cell Engager in China

Fineline Cube May 28, 2026
Policy / Regulatory

NMPA Issues Comprehensive Guidelines for Online Prescription Drug Retail, Mandating Human Pharmacist Review and AI Prescription Blocking

Fineline Cube May 26, 2026
Company Drug

Antengene Receives NMPA Approval for Phase III CLINCH-3 Trial of ATG-022 – CLDN18.2-Targeted ADC Advances in Gastric Cancer with Multi-Region Clinical Strategy

Fineline Cube May 28, 2026
Company Drug

Sino Biopharmaceutical Presents Promising Phase I Data for Kylo-0603 at EASL 2026 – THR-β Agonist Shows 28.5% LDL-C Reduction with Favorable Safety Profile

Fineline Cube May 28, 2026
Company Deals

Gilead Partners with Assembly Biosciences in $84.8 Million Collaboration for Antiviral Therapies

Fineline Cube Oct 18, 2023

Gilead Sciences (NASDAQ: GILD) has announced a significant 12-year collaboration with antiviral specialist Assembly Biosciences...

Company

J&J Reports Strong Q3 2023 Sales Growth Amid Diverse Business Performance

Fineline Cube Oct 18, 2023

Johnson & Johnson (J&J; NYSE: JNJ) has released its Q3 2023 report, revealing impressive global...

Company Deals

Huadong Medicine Secures Global Licensing Agreement for ATGC-110 Botulinum Toxin A Injection

Fineline Cube Oct 18, 2023

China-based Huadong Medicine Co., Ltd. (SHE: 000963) has announced a strategic licensing agreement with South...

Company Deals

Apeloa Pharmaceutical Enters Ten-Year Partnership with Wuhan Hesheng Technology

Fineline Cube Oct 18, 2023

China-based contract development and manufacturing organization (CDMO) Apeloa Pharmaceutical Co., Ltd. (SHE: 000739) has announced...

Company Drug

BeiGene Submits Supplementary BLA for Tislelizumab in Small Cell Lung Cancer

Fineline Cube Oct 18, 2023

BeiGene (NASDAQ: BGNE) has announced that its supplementary Biologic License Application (sBLA) for the programmed...

Company Drug

Mabwell to Present Promising Clinical Data at 2023 ESMO Congress

Fineline Cube Oct 18, 2023

China-based Mabwell (Shanghai) Bioscience Co., Ltd. (SHA: 688062) has announced that it will present the...

Company Deals

Sirius Therapeutics Secures USD 60 Million in Series B Financing for siRNA Therapy Development

Fineline Cube Oct 18, 2023

Sirius Therapeutics, a Shanghai-based developer of siRNA therapies, has successfully raised USD 60 million in...

Company Deals

SciClone Pharmaceuticals Partners with Shanghai Pharmaceutical and Menarini Group

Fineline Cube Oct 18, 2023

China’s SciClone Pharmaceuticals Inc. (HKG: 6600) has entered into a collaborative agreement with Shanghai Pharmaceuticals...

Company Digital

Baidu Launches Interactive AI Medication Instructions Service at Baidu World 2023

Fineline Cube Oct 18, 2023

Robin Li, CEO of China-based internet services giant Baidu, unveiled an innovative interactive AI medication...

Company Deals

Novo Nordisk Strikes $1.3 Billion Deal for KBP Biosciences’ Ocedurenone

Fineline Cube Oct 17, 2023

Denmark-based pharmaceutical giant Novo Nordisk (NYSE: NVO) announced a significant deal this week, valued at...

Company Deals

Ascentage Pharma and AstraZeneca Expand Collaboration on CLL/SLL Treatment

Fineline Cube Oct 17, 2023

China’s Ascentage Pharma (HKG: 6855) and UK-based pharmaceutical giant AstraZeneca (AZ; NASDAQ: AZN) have entered...

Company Drug

Asieris Pharma Launches Generic Votrient for Renal Cell Carcinoma in China

Fineline Cube Oct 17, 2023

China-based urogenital cancer specialist Jiangsu Yahong Meditech Co., Ltd, trading as Asieris Pharma (SHA: 688176),...

Company Drug

BeiGene’s Brukinsa Receives Positive CHMP Opinion for Follicular Lymphoma Treatment

Fineline Cube Oct 17, 2023

China-based biotechnology leader BeiGene (NASDAQ: BGNE; HKG: 6160; SHA: 688235) has announced the receipt of...

Company Deals

EpimAb Biotherapeutics Licenses Bispecific Antibody Platform to Almirall

Fineline Cube Oct 17, 2023

Shanghai-based EpimAb Biotherapeutics has entered into a strategic license agreement with Spanish pharmaceutical company Almirall...

Company Deals

MSD Partners with Phanes Therapeutics for Innovative Cancer Combo Therapy

Fineline Cube Oct 17, 2023

Global pharmaceutical leader Merck, Sharp & Dohme (MSD; NYSE: MRK) has announced a strategic partnership...

Company Deals

Jiangsu Hengrui Licenses Camrelizumab-Apatinib Combo to Elevar Therapeutics

Fineline Cube Oct 17, 2023

China-based pharmaceutical giant Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276) has signed a significant licensing...

Company Drug

Eli Lilly’s Tirzepatide Shows Robust Weight Loss Results in Phase III Study

Fineline Cube Oct 17, 2023

Eli Lilly (NYSE: LLY) has released compelling efficacy results from a Phase III study evaluating...

Company Drug

Simcere’s SIM0237 Receives NMPA Approval for Bladder Cancer Trial

Fineline Cube Oct 17, 2023

China-based pharmaceutical innovator Simcere Pharmaceutical Group (HKG: 2096) has announced the receipt of an additional...

Company Drug

Abbisko Therapeutics to Unveil Phase I Data for ABSK011 and ABSK043 at ESMO 2023

Fineline Cube Oct 17, 2023

Shanghai-based biotech powerhouse Abbisko Therapeutics Co., Ltd (HKG: 2256) is preparing to present the results...

Company Medical Device

MicroPort CardioFlow Medtech’s Third-Generation TAVI Product Achieves Initial Clinical Success

Fineline Cube Oct 17, 2023

MicroPort CardioFlow Medtech Co., Ltd (HKG: 2160), a spin-off from China-based MicroPort Scientific Corp (HKG:...

Posts pagination

1 … 466 467 468 … 673

Recent updates

  • LongBio Pharma Raises HKD 1.25 Billion in Hong Kong IPO – Clinical-Stage Biotech Advances Anti-IgE and Bifunctional Complement Inhibitors for Allergic and Autoimmune Diseases
  • Antengene Receives NMPA Approval for Phase III CLINCH-3 Trial of ATG-022 – CLDN18.2-Targeted ADC Advances in Gastric Cancer with Multi-Region Clinical Strategy
  • J&J Appoints Han Ting as Shanghai-Based Immunology Head While Novartis China Announces Major Restructuring – Dual Leadership Shifts Signal Strategic Repositioning in China Market
  • Sino Biopharmaceutical Presents Promising Phase I Data for Kylo-0603 at EASL 2026 – THR-β Agonist Shows 28.5% LDL-C Reduction with Favorable Safety Profile
  • Dizal Pharmaceutical’s Zegfrovy Receives Priority Review for First-Line EGFR Exon20ins NSCLC – Phase III WU-KONG28 Data Shows Significant PFS Benefit Over Chemotherapy
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

LongBio Pharma Raises HKD 1.25 Billion in Hong Kong IPO – Clinical-Stage Biotech Advances Anti-IgE and Bifunctional Complement Inhibitors for Allergic and Autoimmune Diseases

Company Drug

Antengene Receives NMPA Approval for Phase III CLINCH-3 Trial of ATG-022 – CLDN18.2-Targeted ADC Advances in Gastric Cancer with Multi-Region Clinical Strategy

Company

J&J Appoints Han Ting as Shanghai-Based Immunology Head While Novartis China Announces Major Restructuring – Dual Leadership Shifts Signal Strategic Repositioning in China Market

Company Drug

Sino Biopharmaceutical Presents Promising Phase I Data for Kylo-0603 at EASL 2026 – THR-β Agonist Shows 28.5% LDL-C Reduction with Favorable Safety Profile

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.